Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...
GlobalData on MSN4d
ESMO 2024: Exact Sciences unveils results from cancer algorithm trialThe results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...
Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication ...
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...
Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal ...
“ESMO 2024 will showcase some of our most impactful data in colorectal cancer to-date,” said Minetta Liu, MD, chief medical officer of oncology at Natera. “Notably, we will ...
Westside Current on MSN2d
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other ...SAN FRANCISCO and SUZHOU, China, Sept. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback